AcquisitionsJun 9, 2026, 06:26 AM
GSK to acquire Nuvalent for $10.6B, boosting oncology pipeline
AI Summary
GSK plc announced an agreement to acquire Nuvalent, Inc., a clinical-stage biopharmaceutical company, for $10.6 billion. This strategic acquisition aims to bolster GSK's oncology pipeline with three lung cancer products, including two late-stage, potential best-in-class inhibitors for non-small cell lung cancer (NSCLC) currently under US FDA review for 2026 approvals. The transaction is expected to be accretive to GSK's sales and core operating profit by 2027 and core EPS by 2029, with no change to the company's 2026 financial guidance.
Key Highlights
- GSK will acquire Nuvalent for $10.6 billion, or $124 per share, representing a 40% premium.
- The acquisition includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for NSCLC.
- Both lead assets are under US FDA review with target decision dates in September and November 2026.
- The deal is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029.
- The acquisition accelerates GSK's entry into lung cancer, providing a platform for expansion.
- Funding will primarily come from new and existing debt facilities plus cash, with no impact on GSK's credit rating.
- GSK's 2026 full-year guidance of 7-9% core operating profit and core EPS growth remains unchanged.
Price Impact
More from GSK